Comparison of Moleculin Biotech Inc. (MBRX) and Trillium Therapeutics Inc. (NASDAQ:TRIL)

Moleculin Biotech Inc. (NASDAQ:MBRX) and Trillium Therapeutics Inc. (NASDAQ:TRIL) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Moleculin Biotech Inc. 1 0.00 N/A -0.51 0.00
Trillium Therapeutics Inc. N/A 0.00 N/A -2.55 0.00

In table 1 we can see Moleculin Biotech Inc. and Trillium Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides Moleculin Biotech Inc. and Trillium Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Moleculin Biotech Inc. 0.00% -92.2% -65.2%
Trillium Therapeutics Inc. 0.00% 0% 0%

Insider and Institutional Ownership

Roughly 17.9% of Moleculin Biotech Inc. shares are held by institutional investors while 40.67% of Trillium Therapeutics Inc. are owned by institutional investors. 23.73% are Moleculin Biotech Inc.’s share held by insiders. On the other hand, insiders held about 0.26% of Trillium Therapeutics Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Moleculin Biotech Inc. -5.22% -12.1% -18.05% -20.44% -35.72% 4.81%
Trillium Therapeutics Inc. -1.69% 4.05% -38.77% -80.06% -93.02% -79.59%

For the past year Moleculin Biotech Inc. had bullish trend while Trillium Therapeutics Inc. had bearish trend.


On 4 of the 6 factors Moleculin Biotech Inc. beats Trillium Therapeutics Inc.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company has an agreement with Mayo Clinic to enable additional research on its WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. It also has a strategic collaboration with the University of Bergen to develop immune stimulation drug, as well as to expand research on inhibition of brain metastasis by MoleculinÂ’s pre-clinical drug WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.